{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T14:06:32Z","timestamp":1792850792491,"version":"4.5.0"},"reference-count":152,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T00:00:00Z","timestamp":1747440000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001602","name":"Science Foundation Ireland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001602","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.drudis.2025.104384","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T19:44:01Z","timestamp":1747856641000},"page":"104384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["A review of the efficacy of prostate cancer therapies against castration-resistant prostate cancer"],"prefix":"10.1016","volume":"30","author":[{"given":"Shengxin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma K.","family":"Kinsella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Curtin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104384_b0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.drudis.2025.104384_b0010","article-title":"Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019","volume":"10","author":"Wang","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.drudis.2025.104384_b0015","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41419-022-05084-1","article-title":"Second generation androgen receptor antagonists and challenges in prostate cancer treatment","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2025.104384_b0020","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1080\/14737140.2017.1333903","article-title":"Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment","volume":"17","author":"Anantharaman","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.drudis.2025.104384_b0025","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.eururo.2013.05.029","article-title":"The mutational landscape of prostate cancer","volume":"64","author":"Barbieri","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.drudis.2025.104384_b0030","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.3390\/cells9112494","article-title":"Clinical actionability of the genomic landscape of metastatic castration resistant prostate cancer","volume":"9","author":"Devlies","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2025.104384_b0035","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nrurol.2012.185","article-title":"The complexity of prostate cancer: genomic alterations and heterogeneity","volume":"9","author":"Boyd","year":"2012","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.drudis.2025.104384_b0040","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/pcan.2015.42","article-title":"Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science","volume":"19","author":"Nussbaum","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.drudis.2025.104384_b0045","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12894-019-0527-8","article-title":"Prevalence of fatigue and impact on quality of life in castration-resistant prostate cancer patients: the VITAL study","volume":"19","author":"Rodr\u00edguez Antol\u00edn","year":"2019","journal-title":"BMC Urol"},{"key":"10.1016\/j.drudis.2025.104384_b0050","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.3390\/cancers13112563","article-title":"AR splicing variants and resistance to AR targeting agents","volume":"13","author":"Kanayama","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104384_b0055","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling","volume":"21","author":"Shorning","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104384_b0060","doi-asserted-by":"crossref","first-page":"588","DOI":"10.7150\/ijbs.8671","article-title":"Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer","volume":"10","author":"Kahn","year":"2014","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.drudis.2025.104384_b0065","article-title":"Targeting the tumor microenvironment, a new therapeutic approach for prostate cancer","author":"Fang","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.drudis.2025.104384_b0070","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104384_b0075","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1002\/ptr.8150","article-title":"Unravelling the role of Silibinin in targeting CD44+ cancer stem cells: therapeutic implications, effective strategies and approaches","volume":"38","author":"Lotia","year":"2024","journal-title":"Phytother Res"},{"key":"10.1016\/j.drudis.2025.104384_b0080","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","article-title":"Targeting signaling pathways in prostate cancer: mechanisms and clinical trials","volume":"7","author":"He","year":"2022","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.drudis.2025.104384_b0085","doi-asserted-by":"crossref","first-page":"14847","DOI":"10.3390\/ijms241914847","article-title":"The effect of gene editing by CRISPR-Cas9 of miR-21 and the indirect target MMP9 in metastatic prostate cancer","volume":"24","author":"Camargo","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104384_b0090","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.3390\/molecules28093698","article-title":"PROTACs in the management of prostate cancer","volume":"28","author":"Yedla","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2025.104384_b0095","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.3390\/cancers16132433","article-title":"Role of lutetium radioligand therapy in prostate cancer","volume":"16","author":"Ksi\u0105\u017cek","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104384_b0100","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1002\/pros.24356","article-title":"Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer","volume":"82","author":"Kwan","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.drudis.2025.104384_b0105","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-15-0892","article-title":"The effect of F877L and t878a mutations on androgen receptor response to enzalutamide","volume":"15","author":"Prekovic","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.drudis.2025.104384_b0110","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1634\/theoncologist.2019-0115","article-title":"Comprehensive analysis of AR alterations in circulating tumor dna from patients with advanced prostate cancer","volume":"25","author":"Ledet","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.drudis.2025.104384_b0115","doi-asserted-by":"crossref","first-page":"6935","DOI":"10.1038\/s41388-020-01479-6","article-title":"Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors","volume":"39","author":"Zhu","year":"2020","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2025.104384_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2020.145377","article-title":"Upregulation of potential regulatory signaling molecules correlate with androgen receptor splice variants AR-V7 and AR-V567es in prostate cancer metastasis","volume":"772","author":"Kiliccioglu","year":"2021","journal-title":"Gene"},{"key":"10.1016\/j.drudis.2025.104384_b0125","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.drudis.2020.04.004","article-title":"Advances in the computational development of androgen receptor antagonists","volume":"25","author":"Hu","year":"2020","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.drudis.2025.104384_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188887","article-title":"Cancer stem cell in prostate cancer progression, metastasis and therapy resistance","volume":"1878","author":"Verma","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.drudis.2025.104384_b0135","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ccell.2017.02.004","article-title":"SPOP mutation drives prostate tumorigenesis in vivo through coordinate regulation of PI3K\/mTOR and AR signaling","volume":"31","author":"Blattner","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2025.104384_b0140","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.3390\/ijms23031216","article-title":"Endocrine disruptors and prostate cancer","volume":"23","author":"Corti","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104384_b0145","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.41913","article-title":"GREB1 amplifies androgen receptor output in human prostate cancer and contributes to antiandrogen resistance","volume":"8","author":"Lee","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2025.104384_b0150","doi-asserted-by":"crossref","first-page":"13786","DOI":"10.1038\/s41598-019-50220-1","article-title":"Drivers of AR indifferent anti-androgen resistance in prostate cancer cells","volume":"9","author":"Handle","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104384_b0155","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1158\/2159-8290.CD-24-0559","article-title":"Androgen receptor inhibition increases MHC Class I expression and improves immune response in prostate cancer","volume":"15","author":"Chesner","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2025.104384_b0160","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.canlet.2021.07.012","article-title":"UHRF1 promotes androgen receptor-regulated CDC6 transcription and anti-androgen receptor drug resistance in prostate cancer through KDM4C-mediated chromatin modifications","volume":"520","author":"Gao","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.drudis.2025.104384_b0165","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/s41419-020-02917-9","article-title":"PLC\u025b maintains the functionality of AR signaling in prostate cancer via an autophagy-dependent mechanism","volume":"11","author":"Quan","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2025.104384_b0170","doi-asserted-by":"crossref","first-page":"5464","DOI":"10.7150\/thno.33282","article-title":"KLF5 downregulation desensitizes castration-resistant prostate cancer cells to docetaxel by increasing BECN1 expression and inducing cell autophagy","volume":"9","author":"Jia","year":"2019","journal-title":"Theranostics"},{"key":"10.1016\/j.drudis.2025.104384_b0175","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12943-019-1096-x","article-title":"Prostate cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly","volume":"18","author":"Shi","year":"2019","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2025.104384_b0180","first-page":"3226","article-title":"Epigenetic silencing of miR-137 induces resistance to bicalutamide by targeting TRIM24 in prostate cancer cells","volume":"11","author":"Guan","year":"2019","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.drudis.2025.104384_b0185","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/5806602","article-title":"SPP1 promotes enzalutamide resistance and epithelial-mesenchymal-transition activation in castration-resistant prostate cancer via PI3K\/AKT and ERK1\/2 pathways","volume":"2021","author":"Pang","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"10.1016\/j.drudis.2025.104384_b0190","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1158\/0008-5472.CAN-21-3565","article-title":"A genome-wide CRISPR activation screen identifies PRRX2 as a regulator of enzalutamide resistance in prostate cancer","volume":"82","author":"Rodr\u00edguez","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2025.104384_b0195","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.3390\/cancers13215417","article-title":"Androgen receptor signaling in prostate cancer and therapeutic strategies","volume":"13","author":"Jacob","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104384_b0200","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-3-030-32656-2_16","article-title":"Wnt\/beta-catenin signaling and prostate cancer therapy resistance","volume":"1210","author":"Yeh","year":"2019","journal-title":"Adv. Exp Med Biol"},{"key":"10.1016\/j.drudis.2025.104384_b0205","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s40495-023-00333-z","article-title":"Wnt signaling and therapeutic resistance in castration-resistant prostate cancer","volume":"9","author":"Kishore","year":"2023","journal-title":"Curr Pharmacol Rep"},{"key":"10.1016\/j.drudis.2025.104384_b0210","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8580043","article-title":"The roles of tumor-associated macrophages in prostate cancer","volume":"2022","author":"Han","year":"2022","journal-title":"J Oncol"},{"key":"10.1016\/j.drudis.2025.104384_b0215","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/biom13010067","article-title":"Cancer-associated fibroblast heterogeneity, activation and function: Implications for prostate cancer","volume":"13","author":"Owen","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2025.104384_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.862416","article-title":"Myeloid-derived suppressor cells as key players and promising therapy targets in prostate cancer","volume":"12","author":"Siemi\u0144ska","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2025.104384_b0225","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41419-020-2435-y","article-title":"CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating \u03b2-catenin\/STAT3 signaling","volume":"11","author":"Huang","year":"2020","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2025.104384_b0230","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/pros.21369","article-title":"Macrophages induce neuroendocrine differentiation of prostate cancer cells via BMP6-IL6 Loop","volume":"71","author":"Lee","year":"2011","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.drudis.2025.104384_b0235","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20221007","article-title":"Macrophages promote anti-androgen resistance in prostate cancer bone disease","volume":"220","author":"Li","year":"2023","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2025.104384_b0240","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/j.1464-410X.2010.09804.x","article-title":"Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer","volume":"107","author":"Nonomura","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.drudis.2025.104384_b0245","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.euo.2018.09.014","article-title":"Mannose receptor-positive macrophage infiltration correlates with prostate cancer onset and metastatic castration-resistant disease","volume":"2","author":"Zarif","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.drudis.2025.104384_b0250","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1158\/1078-0432.CCR-17-2446","article-title":"Blocking the feedback loop between neuroendocrine differentiation and macrophages improves the therapeutic effects of enzalutamide (MDV3100) on prostate cancer","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104384_b0255","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1084\/jem.20162024","article-title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","volume":"214","author":"\u00d6hlund","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2025.104384_b0260","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","article-title":"Concepts of extracellular matrix remodelling in tumour progression and metastasis","volume":"11","author":"Winkler","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104384_b0265","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1158\/0008-5472.CAN-10-0785","article-title":"Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness","volume":"70","author":"Giannoni","year":"2010","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.drudis.2025.104384_b0270","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ccell.2020.06.005","article-title":"Tumor microenvironment-derived NRG1 promotes antiandrogen resistance in prostate cancer","volume":"38","author":"Zhang","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2025.104384_b0275","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1152\/physrev.00048.2019","article-title":"Diversity and biology of cancer-associated fibroblasts","volume":"101","author":"Biffi","year":"2021","journal-title":"Physiol Rev"},{"key":"10.1016\/j.drudis.2025.104384_b0280","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","article-title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","volume":"9","author":"Elyada","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2025.104384_b0285","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S1470-2045(22)00278-9","article-title":"Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)","volume":"23","author":"Agarwal","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2025.104384_b0290","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2025.104384_b0295","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1469594","article-title":"VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.drudis.2025.104384_b0300","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1564505","article-title":"Tim-3\/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients","volume":"8","author":"Limagne","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.drudis.2025.104384_b0305","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s00109-021-02123-w","article-title":"Immunosuppressive network promotes immunosenescence associated with aging and chronic inflammatory conditions","volume":"99","author":"Salminen","year":"2021","journal-title":"J Mol Med (Berl)"},{"key":"10.1016\/j.drudis.2025.104384_b0310","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.3389\/fimmu.2018.02499","article-title":"Reactive oxygen species as regulators of MDSC-mediated immune suppression","volume":"9","author":"Ohl","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104384_b0315","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1172\/JCI45862","article-title":"Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice","volume":"121","author":"Lu","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2025.104384_b0320","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1158\/2326-6066.CIR-19-0371","article-title":"Enzalutamide, an androgen receptor antagonist, enhances myeloid cell-mediated immune suppression and tumor progression","volume":"8","author":"Consiglio","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.drudis.2025.104384_b0325","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104384_b0330","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.3390\/cancers15133308","article-title":"Crosstalk between microtubule stabilizing agents and prostate cancer","volume":"15","author":"Chen","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104384_b0335","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.7150\/thno.73152","article-title":"Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy","volume":"12","author":"Ma","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.drudis.2025.104384_b0340","doi-asserted-by":"crossref","first-page":"e1854","DOI":"10.1002\/wnan.1854","article-title":"Current development of cabazitaxel drug delivery systems","volume":"15","author":"Sun","year":"2023","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"key":"10.1016\/j.drudis.2025.104384_b0345","unstructured":"Johnson DB, Sonthalia S. Flutamide. [Updated May 1, 2023]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK482215\/. Accessed August 3, 2024."},{"key":"10.1016\/j.drudis.2025.104384_b0350","first-page":"149","article-title":"Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome","volume":"63","author":"Hara","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2025.104384_b0355","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41585-021-00438-4","article-title":"Resistance to second-generation androgen receptor antagonists in prostate cancer","volume":"18","author":"Schmidt","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.drudis.2025.104384_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsbmb.2018.02.004","article-title":"Discovery and development of ODM-204: a novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1","volume":"192","author":"Oksala","year":"2019","journal-title":"J Steroid Biochem Mol Biol"},{"key":"10.1016\/j.drudis.2025.104384_b0365","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1021\/jm201438f","article-title":"\u201cTrue\u201d antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer","volume":"55","author":"Caboni","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104384_b0370","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1021\/jm200532b","article-title":"Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening","volume":"54","author":"Axerio-Cilies","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104384_b0375","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1021\/jm3015712","article-title":"Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. Development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives","volume":"56","author":"Munuganti","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104384_b0380","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1021\/acscentsci.2c01548","article-title":"Small-molecule inhibition of androgen receptor dimerization as a strategy against prostate cancer","volume":"9","author":"Fu","year":"2023","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.drudis.2025.104384_b0385","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41585-018-0077-y","article-title":"The role of ketoconazole in current prostate cancer care","volume":"15","author":"Patel","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.drudis.2025.104384_b0390","article-title":"Abiraterone-induced hypokalemia: a case report","volume":"15","author":"Nkwocha","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.drudis.2025.104384_b0395","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/pros.24297","article-title":"Abiraterone switches castration\u2010resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling","volume":"82","author":"Moll","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.drudis.2025.104384_b0400","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1006101","article-title":"Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer","volume":"13","author":"Harris","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.drudis.2025.104384_b0405","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/ERC-22-0140","article-title":"Androgen receptor mutations for precision medicine in prostate cancer","volume":"29","author":"Shiota","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.drudis.2025.104384_b0410","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.3390\/ijms21249511","article-title":"Gonadotropin-releasing hormone receptors in prostate cancer: molecular aspects and biological functions","volume":"21","author":"Fontana","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104384_b0415","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2021.07.024","article-title":"Prostate-specific antigen testing as part of a risk-adapted early detection strategy for prostate cancer: European Association of Urology position and recommendations for 2021","volume":"80","author":"Van Poppel","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.drudis.2025.104384_b0420","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3390\/cancers11040434","article-title":"The contributions of prostate cancer stem cells in prostate cancer initiation and metastasis","volume":"11","author":"Mei","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104384_b0425","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/pros.24690","article-title":"CD44 and CD133 protein expression might serve as a prognostic factor for early occurrence castration-resistant prostate cancer","volume":"84","author":"Dwina","year":"2024","journal-title":"Prostate"},{"key":"10.1016\/j.drudis.2025.104384_b0430","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s42003-018-0128-1","article-title":"Frequent mutation of the FOXA1 untranslated region in prostate cancer","volume":"1","author":"Annala","year":"2018","journal-title":"Commun Biol"},{"key":"10.1016\/j.drudis.2025.104384_b0435","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1078-0432.CCR-15-0190","article-title":"Targeting cancer stem cells in castration-resistant prostate cancer","volume":"22","author":"Yun","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104384_b0440","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000455160","article-title":"Cancer stem cells in prostate cancer: implications for targeted therapy","volume":"99","author":"Le\u00e3o","year":"2017","journal-title":"Urol Int"},{"key":"10.1016\/j.drudis.2025.104384_b0445","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1158\/1541-7786.MCR-16-0270-T","article-title":"The efflux transporter ABCG2 maintains prostate stem cells","volume":"15","author":"Sabnis","year":"2017","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.drudis.2025.104384_b0450","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11010-010-0426-5","article-title":"Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1","volume":"340","author":"Liu","year":"2010","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.drudis.2025.104384_b0455","first-page":"43","article-title":"Chapter two \u2013 Dormancy and cancer stem cells: An enigma for cancer therapeutic targeting","volume":"Vol. 141","author":"Talukdar","year":"2019"},{"key":"10.1016\/j.drudis.2025.104384_b0460","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.gendis.2023.02.014","article-title":"Mechanism of PARP inhibitor resistance and potential overcoming strategies","volume":"11","author":"Fu","year":"2024","journal-title":"Genes Dis"},{"key":"10.1016\/j.drudis.2025.104384_b0465","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41401-020-00604-1","article-title":"Response prediction biomarkers and drug combinations of PARP inhibitors in prostate cancer","volume":"42","author":"Chen","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.drudis.2025.104384_b0470","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.3390\/cancers14112804","article-title":"Insights into the possible molecular mechanisms of resistance to PARP inhibitors","volume":"14","author":"Piombino","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104384_b0475","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcac042","article-title":"Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment","volume":"4","author":"Jackson","year":"2022","journal-title":"NAR Cancer"},{"key":"10.1016\/j.drudis.2025.104384_b0480","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1158\/1538-7445.AM2022-1542","article-title":"Abstract 1542: MALAT1 ablation dismantles homologous recombination repair machinery and sensitizes castrate resistant prostate cancer cells to PARP inhibitor","volume":"82","author":"Yadav","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2025.104384_b0485","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.3390\/cancers15194904","article-title":"Hematological toxicities with PARP inhibitors in prostate cancer: a systematic review and meta-analysis of Phase II\/III randomized controlled trials","volume":"15","author":"Bowling","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.drudis.2025.104384_b0490","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3390\/life12091355","article-title":"Comprehensive analysis of adverse events induced by PARP inhibitors using JADER and time to onset","volume":"12","author":"Yamaoka","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.drudis.2025.104384_b0495","first-page":"252","article-title":"PARP inhibitors on the move in prostate cancer: Spotlight on Niraparib & update on PARP inhibitor combination trials","volume":"10","author":"Beatson","year":"2022","journal-title":"Am J Clin Exp Urol"},{"key":"10.1016\/j.drudis.2025.104384_b0500","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1159557","article-title":"PARP inhibitors in metastatic prostate cancer","volume":"13","author":"Taylor","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2025.104384_b0505","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1038\/bjc.2011.163","article-title":"Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer","volume":"104","author":"Mukherjee","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.drudis.2025.104384_b0510","doi-asserted-by":"crossref","first-page":"13375","DOI":"10.1074\/jbc.273.22.13375","article-title":"The tumor suppressor, PTEN\/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate","volume":"273","author":"Maehama","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104384_b0515","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1111\/cas.13636","article-title":"\u03b1-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10","volume":"109","author":"Li","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.drudis.2025.104384_b0520","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrurol.2017.144","article-title":"WNT signalling in prostate cancer","volume":"14","author":"Murillo-Garz\u00f3n","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.drudis.2025.104384_b0525","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nrurol.2017.160","article-title":"Foxy\u20135 in prostate cancer model","volume":"14","author":"Kelsey","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.drudis.2025.104384_b0530","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.1158\/1078-0432.CCR-17-2157","article-title":"A first-in-human Phase I study of the anticancer stem cell agent Ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors","volume":"23","author":"Jimeno","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104384_b0535","doi-asserted-by":"crossref","first-page":"7461","DOI":"10.1038\/sj.onc.1210053","article-title":"Wnts as ligands: processing, secretion and reception","volume":"25","author":"Mikels","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.drudis.2025.104384_b0540","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrd4233","article-title":"Can we safely target the WNT pathway?","volume":"13","author":"Kahn","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104384_b0545","first-page":"587","article-title":"Molecular genetics and targeted therapy of WNT-related human diseases (Review)","volume":"40","author":"Katoh","year":"2017","journal-title":"Int J Mol Med"},{"key":"10.1016\/j.drudis.2025.104384_b0550","doi-asserted-by":"crossref","first-page":"12682","DOI":"10.1073\/pnas.0404875101","article-title":"A small molecule inhibitor of beta-catenin\/CREB-binding protein transcription [corrected]","volume":"101","author":"Emami","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104384_b0555","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0090-4295(02)01589-3","article-title":"Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate","volume":"60","author":"George","year":"2002","journal-title":"Urology"},{"key":"10.1016\/j.drudis.2025.104384_b0560","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","article-title":"Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy","volume":"20","author":"Dvorak","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104384_b0565","doi-asserted-by":"crossref","first-page":"10954","DOI":"10.1073\/pnas.1830978100","article-title":"A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases","volume":"100","author":"Yin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104384_b0570","first-page":"318","article-title":"Alterations in TGF\u03b2 signaling during prostate cancer progression","volume":"9","author":"Thompson-Elliott","year":"2021","journal-title":"Am J Clin Exp Urol"},{"key":"10.1016\/j.drudis.2025.104384_b0575","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3892\/ijo.2017.4129","article-title":"Canonical and non-canonical WNT signaling in cancer stem cells and their niches: cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review)","volume":"51","author":"Katoh","year":"2017","journal-title":"Int J Oncol"},{"key":"10.1016\/j.drudis.2025.104384_b0580","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1016\/j.celrep.2017.05.049","article-title":"Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer","volume":"19","author":"Urbanucci","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2025.104384_b0585","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-13-2665","article-title":"Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary","volume":"20","author":"Kluetz","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104384_b0590","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s00259-020-05169-z","article-title":"[18F]-JK-PSMA-7 and [18F]-FDG tumour PET uptake in treated xenograft human prostate cancer model in mice","volume":"48","author":"Van Simaeys","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.drudis.2025.104384_b0595","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.2967\/jnumed.120.243295","article-title":"Radionuclide therapy in prostate cancer: From standalone to combination PSMA theranostics","volume":"62","author":"Sandhu","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.drudis.2025.104384_b0600","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1158\/1078-0432.CCR-16-3157","article-title":"Ribociclib (LEE011): Mechanism of action and clinical impact of this selective cyclin-dependent kinase 4\/6 inhibitor in various solid tumors","volume":"23","author":"Tripathy","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104384_b0605","doi-asserted-by":"crossref","first-page":"10499","DOI":"10.2147\/OTT.S266085","article-title":"Novel therapeutic strategies for CDK4\/6 inhibitors in metastatic castrate-resistant prostate cancer","volume":"13","author":"Kase","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.drudis.2025.104384_b0610","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","article-title":"Mechanisms of sensitivity and resistance to CDK4\/6 inhibition","volume":"37","author":"\u00c1lvarez-Fern\u00e1ndez","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2025.104384_b0615","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41401-020-0416-4","article-title":"Intrinsic and acquired resistance to CDK4\/6 inhibitors and potential overcoming strategies","volume":"42","author":"Xu","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.drudis.2025.104384_b0620","doi-asserted-by":"crossref","DOI":"10.1002\/adfm.202305506","article-title":"In vitro prostate cancer treatment via CRISPR-Cas9 gene editing facilitated by polyethyleneimine-derived graphene quantum dots","volume":"33","author":"Lee","year":"2023","journal-title":"Adv Funct Mater"},{"key":"10.1016\/j.drudis.2025.104384_b0625","first-page":"7","article-title":"The disruption of Mage-11 gene via CRISPR\/Cas9 method induced apoptosis in the in vitro model of prostate cancer","volume":"1","author":"Farhadi","year":"2023","journal-title":"Gulf J Oncolog"},{"key":"10.1016\/j.drudis.2025.104384_b0630","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1038\/s41467-024-46370-0","article-title":"CRISPR\/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam\/Cabs1 gene cluster expression","volume":"15","author":"Cai","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104384_b0635","article-title":"Principles of CRISPR-Cas9 technology: advancements in genome editing and emerging trends in drug delivery","volume":"92","author":"Aljabali","year":"2024","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.drudis.2025.104384_b0640","first-page":"166","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs","volume":"3","author":"Kim","year":"2011","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.drudis.2025.104384_b0645","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","article-title":"Targeting epigenetic regulators to overcome drug resistance in cancers","volume":"8","author":"Wang","year":"2023","journal-title":"Sig Transduct Target Ther"},{"key":"10.1016\/j.drudis.2025.104384_b0650","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.7_suppl.TPS335","article-title":"ProSTAR: A phase Ib\/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone\/prednisone (A\/P) in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"37","author":"Taplin","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104384_b0655","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1158\/0008-5472.CAN-22-2433","article-title":"LSD1 inhibition disrupts super-enhancer\u2013driven oncogenic transcriptional programs in castration-resistant prostate cancer","volume":"83","author":"Li","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2025.104384_b0660","doi-asserted-by":"crossref","first-page":"11590","DOI":"10.1200\/JCO.2017.35.15_suppl.11590","article-title":"Characterisation of CCS1477: a novel small molecule inhibitor of p300\/CBP for the treatment of castration resistant prostate cancer","volume":"35","author":"Pegg","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104384_b0665","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1756287215597637","article-title":"Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials","volume":"7","author":"Kaushik","year":"2015","journal-title":"Ther Adv Urol"},{"key":"10.1016\/j.drudis.2025.104384_b0670","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-17-3571","article-title":"Targeting bromodomain and extra-terminal (BET) family proteins in castration-resistant prostate cancer (CRPC)","volume":"24","author":"Welti","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.drudis.2025.104384_b0675","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urolonc.2009.09.015","article-title":"Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemona\u00efve castration-resistant prostate cancer","volume":"29","author":"Sonpavde","year":"2011","journal-title":"Urol Oncol"},{"issue":"6","key":"10.1016\/j.drudis.2025.104384_b0680","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.ccell.2018.11.005","article-title":"Resistance to epigenetic-targeted therapy engenders tumor cell vulnerabilities associated with enhancer remodeling","volume":"34","author":"Iniguez","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.drudis.2025.104384_b0685","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41571-021-00499-9","article-title":"Novel approaches to target the microenvironment of bone metastasis","volume":"18","author":"Hofbauer","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104384_b0690","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41572-020-00216-3","article-title":"Bone metastases","volume":"6","author":"Coleman","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.drudis.2025.104384_b0695","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1080\/14712598.2020.1814731","article-title":"Denosumab for cancer-related bone loss","volume":"20","author":"Dell\u2019Aquila","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.drudis.2025.104384_b0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2024.122469","article-title":"Nanotherapeutics for prostate cancer treatment: a comprehensive review","volume":"305","author":"Hu","year":"2024","journal-title":"Biomaterials"},{"key":"10.1016\/j.drudis.2025.104384_b0705","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jconrel.2021.01.010","article-title":"Targeting therapy for prostate cancer by pharmaceutical and clinical pharmaceutical strategies","volume":"333","author":"Sun","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2025.104384_b0710","doi-asserted-by":"crossref","DOI":"10.47611\/jsrhs.v11i2.2607","article-title":"Review of the clinical trial failures of nanomedicines targeting cancer","volume":"11","author":"Mukherjee","year":"2022","journal-title":"J Stud Res"},{"key":"10.1016\/j.drudis.2025.104384_b0715","first-page":"142","article-title":"Functionalized nanoparticles targeting biomarkers for prostate cancer imaging and therapy","volume":"10","author":"Choksi","year":"2022","journal-title":"Am J Clin Exp Urol"},{"key":"10.1016\/j.drudis.2025.104384_b0720","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3390\/ph16020315","article-title":"PSMA-targeted nanotheranostics for imaging and radiotherapy of prostate cancer","volume":"16","author":"Meher","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.drudis.2025.104384_b0725","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1039\/D2TB00531J","article-title":"AuNCs\u2013LHRHa nano-system for FL\/CT dual-mode imaging and photothermal therapy of targeted prostate cancer","volume":"10","author":"Wang","year":"2022","journal-title":"J Mater Chem B"},{"key":"10.1016\/j.drudis.2025.104384_b0730","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2022043827","article-title":"Nanotherapeutic approach to delivery of chemo- and gene therapy for organ-confined and advanced castration-resistant prostate cancer","volume":"40","author":"Sharma","year":"2023","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.drudis.2025.104384_b0735","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105212","article-title":"Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy","volume":"105","author":"Zhang","year":"2024","journal-title":"EBioMedicine"},{"key":"10.1016\/j.drudis.2025.104384_b0740","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS290","article-title":"A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Petrylak","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2025.104384_b0745","doi-asserted-by":"crossref","first-page":"10917","DOI":"10.1021\/acs.jmedchem.3c00736","article-title":"Small-molecule hydrophobic tagging: A promising strategy of druglike technology for targeted protein degradation","volume":"66","author":"Xie","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.drudis.2025.104384_b0750","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.70700","article-title":"Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer","volume":"12","author":"Wu","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.drudis.2025.104384_b0755","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1021\/acsmedchemlett.9b00115","article-title":"Treatment of prostate cancers and Kennedy\u2019s disease by PROTAC-androgen receptor degradation","volume":"10","author":"Kargbo","year":"2019","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.drudis.2025.104384_b0760","doi-asserted-by":"crossref","first-page":"6764","DOI":"10.1158\/1078-0432.CCR-19-1458","article-title":"Orally bioavailable androgen receptor degrader, potential next-generation therapeutic for enzalutamide-resistant prostate cancer","volume":"25","author":"Ponnusamy","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625000972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625000972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T18:02:00Z","timestamp":1749664920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625000972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":152,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1359644625000972"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104384","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of the efficacy of prostate cancer therapies against castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104384","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104384"}}